Eris Lifesciences has entered into a joint venture with MJ Biopharm to distribute human insulin, insulin analogues and GLP1 agonists. Eris will have a 70 per cent stake whereas MJ will hold 30 per cent. On completion, MJ will be paid a one-time lumpsum licence fee of Rs 15 crore.

The joint venture will launch human insulin early next year and other products in due course. Eris will handle distribution and sales and marketing, whereas MJ Biopharm will supply products for 10 years.

"With the formation of this JV with MJ, we are taking our commitment a step further. Over the next 10-15 years, growth in diabetes care will be driven by DPP4-SGLT2 combinations, Insulin Analogues and GLP1 agonists, given the superior clinical evidence on their ability to provide better glycemic control, cardio-renal protection, and weight management," Eris Lifesciences Chairman and Managing Director Amit Bakshi said in a statement.

"I am excited about this collaboration with Eris and we look forward to expand the breadth and depth of the Insulin market in India," MJ Biopharm Managing Director Amol Shah stated.

Mumbai based MJ Biopharm is into the development and commercialisation of recombinant biosimilar formulations, with manufacturing facilities in India for biologics bulk and formulations based on the microbial fermentation platform.